496 related articles for article (PubMed ID: 16377584)
1. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
4. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
[TBL] [Abstract][Full Text] [Related]
5. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
11. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
[TBL] [Abstract][Full Text] [Related]
12. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
14. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.
Bourgeois H; Joly F; Pujade-Lauraine E; Cure H; Guastalla JP; Ferru A; Chabrun V; Chieze S; Tourani JM
Am J Clin Oncol; 2006 Aug; 29(4):399-404. PubMed ID: 16891870
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
Iqbal S; Tsao-Wei DD; Quinn DI; Gitlitz BJ; Groshen S; Aparicio A; Lenz HJ; El-Khoueiry A; Pinski J; Garcia AA
Am J Clin Oncol; 2011 Feb; 34(1):27-31. PubMed ID: 20142723
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
19. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]